Compare Salesforce Inc (CRM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Medpace Holdings Inc — how do they compare? Salesforce Inc trades at $167.14 (market cap $137.23B), while Medpace Holdings Inc trades at $526.66 (market cap $15.31B). The key difference: Salesforce Inc is far larger — about 9× Medpace Holdings Inc's market cap, and Salesforce Inc pays a 1.05% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CRM | MEDP | |
|---|---|---|
Market Cap | $137.23B | $15.31B |
Sector | Technology | Technology |
52-Week High | $270.25 | $620.59 |
52-Week Low | $150.12 | $308.88 |
Enterprise Value | $167.28B | $14.78B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.00, down 2.46% amid broader software sector weakness. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected), robust 77.64% gross margins, and 18.73% net income margin. Technical indicators are neutral with support at $165 and resistance at $171. Recent news highlights AI momentum with Agentforce ARR reaching $2.9B, though sector-wide AI concerns have pressured software stocks.
Outlook remains positive with analyst consensus target of $235.90 (41% upside) and 77% buy ratings. Key opportunities include AI monetization growth and expanding profit margins, while risks involve sector volatility and competitive AI landscape. The current valuation at 19.42 P/E appears reasonable given double-digit revenue growth and strong cash flow generation.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
